<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Year-to-date, Canopy Growth (NASDAQ:CGC) stock lost 68.45%, compared to AdvisorShares Pure Cannabis ETF (NYSE:YOLO) that went down 33.94%, and SPDR S&P 500 (NYSE:SPY) gaining 21.83%. Just last week the Canadian cannabis giant confirmed it is divesting its subsidiary business , C3 Cannabinoid Compound Company GmbH, to Dermapharm Holding SE, a European pharmaceutical company headquartered in Grünwald, Germany.
...read full article on Benzinga
